SCHEDULE: Highbridge Boosts Matinas BioPharma Stake to 8.4%

Highbridge Capital Management, LLC has reported an 8.4% beneficial ownership stake in Matinas BioPharma Holdings, Inc., primarily through warrants.

Summary

• Highbridge Capital Management, LLC reported beneficial ownership of 466,667 shares of Matinas BioPharma Holdings, Inc. Common Stock.
• This represents an 8.4% stake in the company's outstanding Common Stock.
• The shares are issuable upon the exercise of warrants directly held by the Highbridge Funds.
• The percentage is calculated based on 5,086,985 shares of Common Stock outstanding as of May 15, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q.
• Highbridge Capital Management, LLC serves as the investment adviser to the Highbridge Funds.
• Highbridge Tactical Credit Master Fund, L.P., a Highbridge Fund, holds the right to receive or direct the receipt of dividends or proceeds from the sale of more than 5% of the shares of Common Stock.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects, beyond the fact of institutional investment.

Positives

• A notable institutional investor, Highbridge Capital Management, LLC, has disclosed a significant beneficial ownership stake, indicating potential confidence or strategic interest in the company.
• The stake is held through warrants, suggesting a prior investment or financing arrangement that brought capital to the company.

Negatives

• The beneficial ownership being primarily through warrants could imply past dilutive financing events for the issuer, which might have impacted existing shareholder value.

Risks

• The filing explicitly states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, nor in connection with any transaction having that purpose or effect.

Future Outlook

N/A. This filing is a beneficial ownership report and does not contain forward-looking statements or guidance from the issuer or reporting person regarding future performance or strategy.

Industry Context

This filing reflects a routine disclosure of significant beneficial ownership by an institutional investment firm in a biopharmaceutical company, common in the financial markets as part of regulatory transparency requirements.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and potentially signal investor interest.
• Company Management: Awareness of a significant institutional holder and its stake, which may influence future engagement or strategic considerations.

Key Dates

Keywords

Matinas BioPharma, Highbridge Capital Management, Beneficial Ownership, Warrants, SEC Filing, Schedule 13G, Investment Adviser, Common Stock, Biopharma